108 related articles for article (PubMed ID: 17611692)
1. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.
Shnyder SD; Cooper PA; Millington NJ; Pettit GR; Bibby MC
Int J Oncol; 2007 Aug; 31(2):353-60. PubMed ID: 17611692
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.
Prokopiou EM; Cooper PA; Pettit GR; Bibby MC; Shnyder SD
Mol Med Rep; 2010; 3(2):309-13. PubMed ID: 21472238
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
4. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
Cullis ER; Kalber TL; Ashton SE; Cartwright JE; Griffiths JR; Ryan AJ; Robinson SP
Microvasc Res; 2006 Mar; 71(2):76-84. PubMed ID: 16530791
[TBL] [Abstract][Full Text] [Related]
5. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum.
Fennell BJ; Carolan S; Pettit GR; Bell A
J Antimicrob Chemother; 2003 Apr; 51(4):833-41. PubMed ID: 12654761
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
7. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells.
Sato M; Sagawa M; Nakazato T; Ikeda Y; Kizaki M
Int J Oncol; 2007 Jun; 30(6):1453-9. PubMed ID: 17487366
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor effects of TZT-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice].
Fujita F; Koike M; Fujita M; Sakamoto Y; Tsukagoshi S
Gan To Kagaku Ryoho; 2000 Mar; 27(3):451-8. PubMed ID: 10740640
[TBL] [Abstract][Full Text] [Related]
11. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
12. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Radiother Oncol; 2006 Feb; 78(2):138-45. PubMed ID: 16455148
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of 3,5,4'-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice.
Pan MH; Gao JH; Lai CS; Wang YJ; Chen WM; Lo CY; Wang M; Dushenkov S; Ho CT
Mol Carcinog; 2008 Mar; 47(3):184-96. PubMed ID: 18085528
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of selected natural products as therapeutic agents against cancer.
Banerjee S; Wang Z; Mohammad M; Sarkar FH; Mohammad RM
J Nat Prod; 2008 Mar; 71(3):492-6. PubMed ID: 18302335
[TBL] [Abstract][Full Text] [Related]
15. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
Grosios K; Holwell SE; McGown AT; Pettit GR; Bibby MC
Br J Cancer; 1999 Dec; 81(8):1318-27. PubMed ID: 10604728
[TBL] [Abstract][Full Text] [Related]
17. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Ji YB; Zhou JH; Zuo MX; You QD
Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice.
Gil-Ad I; Zolokov A; Lomnitski L; Taler M; Bar M; Luria D; Ram E; Weizman A
Int J Oncol; 2008 Aug; 33(2):277-86. PubMed ID: 18636148
[TBL] [Abstract][Full Text] [Related]
19. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).
Newman RA; Fuentes A; Covey JM; Benvenuto JA
Drug Metab Dispos; 1994; 22(3):428-32. PubMed ID: 8070319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
